Actively Recruiting
Phase I Open-Label Study Evaluating Safety and Efficacy of XS-02 Capsules in Advanced Solid Tumors
Led by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Updated on 2026-10-26
96
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, open-label Phase I study to evaluate XS-02 capsules in patients with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetics, and initial efficacy of XS-02 in patients who have locally advanced or metastatic solid tumors, including ovarian, breast, endometrial cancers, and osteosarcoma. This study is designed to find appropriate dosing and observe early effects in this patient group. Participants will receive XS-02 capsules orally once daily during a Phase I dose-escalation period, where dosage and administration schedules may be adjusted based on results. Following this, a dose-expansion phase will identify the optimal dose to study further. The treatment is administered sequentially, with doses ranging from 5 mg to 25 mg as capsules. Treatment continues under medical supervision with adjustments as needed. Participants will undergo various assessments including safety monitoring, pharmacokinetic testing up to 20 weeks, and tumor evaluations based on RECIST v1.1 criteria. Outcome measures include observing dose-limiting toxicities within 31 days, determining maximum tolerated dose and recommended Phase II dose, and tracking objective response rates and other efficacy indicators over about three years. Safety and laboratory tests, biomarker analysis, imaging, and regular follow-up visits are part of the study schedule to monitor participant health and treatment effects throughout the trial.
CONDITIONS
Brief Title
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Research Team
L
Lingying Wu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here